MARIBETH HATALSKI: Open Payments
NPI 1023426954 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,652 in 142 payments from 20 companies in 2025. Trend: 2023 $2,116 · 2024 $3,436 · 2025 $3,652
Food & beverage: $3,568Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 25 | $833 |
| ABBVIE INC. | 21 | $532 |
| Ardelyx, Inc. | 10 | $380 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $368 |
| Madrigal Pharmaceuticals | 12 | $274 |
| PFIZER INC. | 10 | $260 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $259 |
| QOL Medical, LLC | 12 | $186 |
| GENZYME CORPORATION | 5 | $103 |
| Ipsen Biopharmaceuticals, Inc | 4 | $91 |
Products named: TREMFYA, IBSRELA, RINVOQ, ENTYVIO, REZDIFFRA, XIFAXAN, Sucraid, VELSIPITY.
Industry payments across MD — which companies pay providers there.
